3.31
price up icon3.44%   0.11
after-market After Hours: 3.24 -0.07 -2.11%
loading
Arbutus Biopharma Corp stock is traded at $3.31, with a volume of 592.72K. It is up +3.44% in the last 24 hours and down -2.36% over the past month. Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
See More
Previous Close:
$3.20
Open:
$3.2
24h Volume:
592.72K
Relative Volume:
0.73
Market Cap:
$624.87M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-7.5227
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+3.76%
1M Performance:
-2.36%
6M Performance:
-20.05%
1Y Performance:
+32.40%
1-Day Range:
Value
$3.20
$3.32
1-Week Range:
Value
$3.16
$3.505
52-Week Range:
Value
$2.30
$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name
Name
Arbutus Biopharma Corp
Name
Phone
604-419-3200
Name
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Name
Employee
73
Name
Twitter
@arbutusbio
Name
Next Earnings Date
2025-03-19
Name
Latest SEC Filings
Name
ABUS's Discussions on Twitter

Compare ABUS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ABUS
Arbutus Biopharma Corp
3.31 624.87M 12.99M -74.39M -78.92M -0.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
512.52 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.36 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
619.97 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.44 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
266.26 28.62B 3.81B -644.79M -669.77M -6.24

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-02-22 Upgrade Jefferies Hold → Buy
Feb-25-21 Initiated Jefferies Hold
Dec-17-20 Initiated H.C. Wainwright Buy
Jul-27-20 Resumed JMP Securities Mkt Outperform
Jul-24-20 Downgrade Robert W. Baird Outperform → Neutral
May-19-20 Upgrade Wedbush Neutral → Outperform
Mar-06-20 Upgrade Chardan Capital Markets Neutral → Buy
Feb-20-20 Initiated Robert W. Baird Outperform
Feb-05-20 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Oct-07-19 Reiterated B. Riley FBR Buy
Oct-04-19 Downgrade Chardan Capital Markets Buy → Neutral
Oct-16-18 Upgrade B. Riley FBR Neutral → Buy
Oct-15-18 Upgrade Wedbush Underperform → Neutral
Oct-12-18 Reiterated Chardan Capital Markets Buy
Jul-06-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Mar-19-18 Resumed Chardan Capital Markets Buy
Mar-19-18 Downgrade Wedbush Outperform → Neutral
Jan-05-18 Initiated B. Riley FBR, Inc. Buy
Apr-04-17 Upgrade Chardan Capital Markets Neutral → Buy
Feb-01-17 Reiterated Wedbush Outperform
Dec-13-16 Downgrade Chardan Capital Markets Buy → Neutral
Nov-30-16 Upgrade Chardan Capital Markets Neutral → Buy
View All

Arbutus Biopharma Corp Stock (ABUS) Latest News

pulisher
Mar 08, 2025

FY2025 Earnings Forecast for ABUS Issued By Chardan Capital - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Are Arbutus Biopharma Corp’shares a good deal? - US Post News

Mar 07, 2025
pulisher
Mar 05, 2025

Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Moderna Faces MRNA Vax Patent Suits In Canada And Beyond - Law360

Mar 04, 2025
pulisher
Mar 03, 2025

Genevant Sciences and Arbutus Biopharma File International Lawsuits Against Moderna for Patent Infringement of Lipid Nanoparticle Technology - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global - StockTitan

Mar 03, 2025
pulisher
Feb 28, 2025

Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

StockNews.com Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Sell - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Brokers Issue Forecasts for ABUS FY2029 Earnings - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Brokers Set Expectations for ABUS FY2029 Earnings - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Arbutus Biopharma (NASDAQ:ABUS) Lowered to “Sell” Rating by StockNews.com - Defense World

Feb 26, 2025
pulisher
Feb 26, 2025

Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring - MyChesCo

Feb 26, 2025
pulisher
Feb 25, 2025

Lindsay Androski named CEO of Arbutus - BioCentury

Feb 25, 2025
pulisher
Feb 25, 2025

Arbutus Biopharma appoints new CEO and reshapes board - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - The Manila Times

Feb 25, 2025
pulisher
Feb 24, 2025

Arbutus Biopharma Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Feb 24, 2025
pulisher
Feb 20, 2025

Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool

Feb 20, 2025
pulisher
Feb 20, 2025

Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN

Feb 20, 2025
pulisher
Feb 12, 2025

The Hidden Gem in Nasdaq’s Under $5 Club: Is Arbutus Biopharma the Next Big Thing? - Jomfruland.net

Feb 12, 2025
pulisher
Feb 12, 2025

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

Ebola Virus Vaccine Market May See a Big Move| Arbutus Biopharma, BioCryst Pharmaceuticals - openPR

Feb 11, 2025
pulisher
Feb 11, 2025

10 Best Nasdaq Stocks Under $5 to Buy - Insider Monkey

Feb 11, 2025
pulisher
Feb 08, 2025

SG Americas Securities LLC Purchases 16,250 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Feb 08, 2025
pulisher
Feb 06, 2025

Arbutus Biopharma Corp (ABUS) Stock: A Look at the Monthly Trend - The News Heater

Feb 06, 2025
pulisher
Feb 05, 2025

Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Jefferies analysts upgrades a Buy rating for Arbutus Biopharma Corp (ABUS) - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Arbutus Biopharma Executives Sell Shares to Cover Tax Obligations - TradingView

Feb 05, 2025
pulisher
Feb 04, 2025

Arbutus Biopharma Corp (ABUS) expanding its growth trajectory ahead - SETE News

Feb 04, 2025
pulisher
Feb 03, 2025

Morgan Stanley Reduces Stake in Arbutus Biopharma Corp - GuruFocus.com

Feb 03, 2025
pulisher
Jan 30, 2025

JPMorgan Chase & Co. Increases Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jan 30, 2025
pulisher
Jan 27, 2025

Ballentine Partners LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

Arbutus Biopharma Corp. to Host Earnings Call - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 22, 2025

Arbutus Biopharma (NASDAQ:ABUS) Receives “Buy” Rating from HC Wainwright - Defense World

Jan 22, 2025
pulisher
Jan 21, 2025

Arbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Jan 21, 2025
pulisher
Jan 17, 2025

Arbutus Biopharma Sets Sights on Advancing HBV Cure in 2025 - MyChesCo

Jan 17, 2025
pulisher
Jan 16, 2025

Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’ - Insider Monkey

Jan 16, 2025
pulisher
Jan 15, 2025

Barclays PLC Purchases 223,995 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

Cramer's Lightning Round: Arbutus Biopharma is 'the ultimate spec' - MSN

Jan 13, 2025
pulisher
Jan 13, 2025

Arbutus Provides 2025 Corporate and Financial Update - GlobeNewswire

Jan 13, 2025
pulisher
Jan 11, 2025

Jane Street Group LLC Has $258,000 Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jan 11, 2025
pulisher
Jan 08, 2025

Principal Financial Group Inc. Sells 12,352 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jan 08, 2025
pulisher
Jan 07, 2025

Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseShould You Buy? - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development (NASDAQ:ABUS) - Seeking Alpha

Jan 07, 2025
pulisher
Dec 31, 2024

Geode Capital Management LLC Buys 135,442 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Dec 31, 2024

Arbutus Biopharma Corp Stock (ABUS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.94
price up icon 2.53%
$318.85
price up icon 1.51%
$33.41
price up icon 0.00%
$20.11
price up icon 1.41%
$99.27
price up icon 0.31%
biotechnology ONC
$266.26
price up icon 1.87%
Cap:     |  Volume (24h):